SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Contact NPG
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
21 January 2002, Volume 21, Number 4, Pages 494-502
Table of contents    Previous  Abstract  Next   Full text  PDF
Telomerase is not an oncogene
Calvin B Harley

Geron Corporation, Menlo Park, California, CA 94025, USA

Correspondence to: C B Harley, Geron Corporation, 230 Constitution Drive, Menlo Park, California, CA 94025, USA; E-mail: charley@geron.com


In the decade since the telomere hypothesis of cellular aging was proposed, the two essential genes for human telomerase were cloned and characterized, allowing experimental proof of the causal relationships between telomere loss and replicative senescence, and telomerase activation and immortalization. These relationships were established using a variety of cultured human cell types from both normal and tumor tissues, and were largely confirmed in the telomerase knockout mouse. Taken together, the data provide strong support for the potential utility of telomerase detection and inhibition for cancer, and telomerase activation for degenerative diseases. The specificity of the promoter for the telomerase catalytic gene and the antigenicity of the protein product, hTERT, provide additional strategies for killing telomerase-positive tumor cells. Unfortunately, the strong link between telomerase and cancer has led some to confuse telomerase activation with cancer, and others to overstate the cancer risk of telomerase activation therapies for degenerative diseases. This review clarifies the difference between telomerase, which does not cause growth deregulation, and oncogenes, which do. It also addresses the concept of telomerase repression as a tumor suppressor mechanism early in life, with detrimental tissue degeneration and tumor-promoting consequences late in life. This extended view of the telomere hypothesis helps explain how telomerase inhibition can be therapeutic in cancer patients, while controlled telomerase activation for degenerative diseases may actually reduce, rather than increase, the frequency of age-related tumorigenesis.

Oncogene (2002) 21, 494-502 DOI: 10.1038/sj/onc/1205076


telomere; telomerase; aging; cancer; immortalization; genetic instability

21 January 2002, Volume 21, Number 4, Pages 494-502
Table of contents    Previous  Abstract  Next   Full text  PDF